drugset / Trial / NCT00004932
STI571 in Treating Patients With Recurrent Leukemia
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Imatinib mesylate may interfere with the growth of cancer cells and may be an effective treatment for leukemia. PURPOSE: Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have recurrent leukemia.
Timeline
- Start
- 2002-01
- Primary completion
- 2005-09
- Completion
- 2005-09
Publications
- Results Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, Therrien M, Zoellner U, Blaney SM, Bernstein M; Children's Oncology Group phase 1 study. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004 Nov 1;104(9):2655-60. doi: 10.1182/blood-2003-09-3032. Epub 2004 Jul 1.
- Results Champagne MA, Hershon L, Rosamilia M, et al.: STI571 in the Treatment of Pediatric Philadelphia (Ph+) Chromosome-Positive Leukemia: A Children's Oncology Group Phase 1 Study (P-9973). [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1466, 2001.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 260 mg/m2 | Oral |
| Subject | Imatinib | Small molecule | 340 mg/m2 | Oral |
| Subject | Imatinib | Small molecule | 440 mg/m2 | Oral |
| Subject | Imatinib | Small molecule | 570 mg/m2 | Oral |